AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

Rhea-AI Summary

AcelRx Pharmaceuticals will release its third quarter 2023 financial results on November 8th and host a webcast and conference call to discuss the results and provide a business update.

Positive

• Investors can access the webcast on the company's website and a replay will be available for 90 days.

Negative

• None.

HAYWARD, Calif., Oct. 26, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2023 financial results after market close on Wednesday, November 8, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide an update on the Company's business.  

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and clicking on the webcast link within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the AcelRx website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 (toll applies) for international callers. The conference ID is 10182244.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. AcelRx is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-third-quarter-2023-financial-results-call-and-webcast-on-november-8-2023-301969382.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When will AcelRx Pharmaceuticals release its third quarter 2023 financial results?

AcelRx Pharmaceuticals will release its third quarter 2023 financial results on November 8, 2023.

How can investors access the webcast?

Investors can access the webcast on the company's website at www.acelrx.com.

Will there be a replay of the webcast?

Yes, a replay of the webcast will be available on the AcelRx website for 90 days following the event.

What will be discussed during the webcast and conference call?

The webcast and conference call will discuss the third quarter 2023 financial results and provide an update on the company's business.

What is the conference call dial-in information?

Domestic callers can dial 1-866-361-2335, Canadian callers can dial 1-855-669-9657, and international callers can dial 1-412-902-4204 (toll applies). The conference ID is 10182244.